Syndax Pharma (SNDX) Stock Price, Quote & News

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 419 1400

Website: syndax.com

Address:

730 Third Avenue, 9th Floor, New York, United States

cchronobreak Oct. 25 at 10:31 AM

$SNDX

0 · Reply

CH_Expat Oct. 25 at 8:18 AM

$SNDX Who sold CTIC back then? And who is our CEO? The new arrival for the BOD has a history at which company we shares profits with for which drug? Connect the dots. Ignore the idiots.

0 · Reply

CH_Expat Oct. 25 at 8:14 AM

$SNDX One of my preferred setups for substantial wins is this here. Selloff on good or no news with high institutional ownership. Nothing but manipulation to suck up more shares for the whales. Starter here and double every 10% down. Ignore idiots, stick to fundamentals. EV 600m for a drug that has, all weaknesses aside easily 1 billion dollar peak sales. Is this fair value at 1.2b MC? I say no.

1 · Reply

CH_Expat Oct. 25 at 7:37 AM

$SNDX Approval shakeout, seen so many times. Ignore fudsters, opening positions at this price bring you profits in a foreseeable future.

1 · Reply

urthousk Oct. 25 at 6:22 AM

$NVDA $TSLA $SNDX $INOD ;; https://stocktwits.com/urthousk/message/633694291

0 · Reply

LongLongStock Oct. 25 at 6:08 AM

$SNDX i think stock usually goes down on pdufa, but if this stock is heavily own by institutions, and management executes, this could 3x to 6x within the next year

0 · Reply

Candycaneispeppermint Oct. 25 at 5:35 AM

$SNDX ? It was always Kura that wins this market. The FDA has spoken.

1 · Reply

WallStreetBuyDip Oct. 25 at 3:53 AM

I'm not the one to trade based on momentum, will buy $SNDX when H% is low like I did here

1 · Reply

Habanacuba Oct. 25 at 3:44 AM

$SNDX Don't you think that starting next week some analysts will raise their PT?

0 · Reply

FreddieMercury91 Oct. 25 at 3:33 AM

$SNDX all going to lose all our money

0 · Reply

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

$Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Oct 24, 2025, 1:58 PM EDT - 16 hours ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Oct 15, 2025, 2:30 PM EDT - 9 days ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY INCY XBI

Oct 9, 2025, 5:00 PM EDT - 15 days ago

Making Money In Biotech Stocks

GERN

Oct 3, 2025, 4:01 PM EDT - 21 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS TVTX

$Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Sep 19, 2025, 7:00 AM EDT - 5 weeks ago

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Sep 10, 2025, 6:10 PM EDT - 6 weeks ago

Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

Sep 2, 2025, 7:50 PM EDT - 7 weeks ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Syndax Announces Participation in September Investor Conferences

Aug 13, 2025, 6:34 PM EDT - 2 months ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 5, 2025, 12:59 PM EDT - 2 months ago

Syndax Pharmaceuticals: The Story Brightens

Aug 4, 2025, 11:52 PM EDT - 2 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Jul 8, 2025, 5:18 AM EDT - 3 months ago

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

$Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia$

Jun 24, 2025, 4:01 PM EDT - 4 months ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Jun 12, 2025, 12:02 PM EDT - 4 months ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

$Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025$

Jun 12, 2025, 7:00 AM EDT - 4 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

May 29, 2025, 7:00 AM EDT - 5 months ago

Syndax Announces Participation in June Investor Conferences

May 14, 2025, 9:30 AM EDT - 5 months ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 12, 2025, 4:01 PM EDT - 5 months ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 8, 2025, 7:00 AM EDT - 6 months ago

Syndax Announces Participation in May Investor Conferences

$Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood$

May 7, 2025, 4:01 PM EDT - 6 months ago

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 5, 2025, 11:18 PM EDT - 6 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:01 PM EDT - 6 months ago

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 7:00 AM EDT - 6 months ago

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Apr 2, 2025, 7:00 AM EDT - 7 months ago

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Mar 3, 2025, 11:46 AM EST - 8 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:01 AM EST - 8 months ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 7:00 AM EST - 8 months ago

Syndax Announces Participation in March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 8 months ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Feb 10, 2025, 5:42 PM EST - 9 months ago

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Jan 30, 2025, 7:00 AM EST - 9 months ago

Syndax Announces Participation in February Investor Conferences

Jan 15, 2025, 5:34 PM EST - 10 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

INCY

Jan 13, 2025, 7:00 AM EST - 10 months ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 10 months ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

$Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial$

Dec 9, 2024, 7:30 AM EST - 11 months ago

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Dec 7, 2024, 6:15 PM EST - 11 months ago

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Nov 27, 2024, 7:00 AM EST - 11 months ago

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Nov 15, 2024, 6:26 PM EST - 1 year ago

US FDA approves Syndax's blood cancer drug

$Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation$

Nov 15, 2024, 5:29 PM EST - 1 year ago

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Nov 12, 2024, 4:34 PM EST - 1 year ago

Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity

$Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib$

Nov 12, 2024, 7:00 AM EST - 1 year ago

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Nov 5, 2024, 8:39 PM EST - 1 year ago

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 1 year ago

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:01 AM EST - 1 year ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

Nov 5, 2024, 9:00 AM EST - 1 year ago

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

cchronobreak Oct. 25 at 10:31 AM

$SNDX

0 · Reply

CH_Expat Oct. 25 at 8:18 AM

$SNDX Who sold CTIC back then? And who is our CEO? The new arrival for the BOD has a history at which company we shares profits with for which drug? Connect the dots. Ignore the idiots.

0 · Reply

CH_Expat Oct. 25 at 8:14 AM

1 · Reply

CH_Expat Oct. 25 at 7:37 AM

$SNDX Approval shakeout, seen so many times. Ignore fudsters, opening positions at this price bring you profits in a foreseeable future.

1 · Reply

urthousk Oct. 25 at 6:22 AM

$NVDA $TSLA $SNDX $INOD ;; https://stocktwits.com/urthousk/message/633694291

0 · Reply

LongLongStock Oct. 25 at 6:08 AM

$SNDX i think stock usually goes down on pdufa, but if this stock is heavily own by institutions, and management executes, this could 3x to 6x within the next year

0 · Reply

Candycaneispeppermint Oct. 25 at 5:35 AM

$SNDX ? It was always Kura that wins this market. The FDA has spoken.

1 · Reply

WallStreetBuyDip Oct. 25 at 3:53 AM

I'm not the one to trade based on momentum, will buy $SNDX when H% is low like I did here

1 · Reply

Habanacuba Oct. 25 at 3:44 AM

$SNDX Don't you think that starting next week some analysts will raise their PT?

0 · Reply

FreddieMercury91 Oct. 25 at 3:33 AM

$SNDX all going to lose all our money

0 · Reply

BrunetteSara Oct. 25 at 3:14 AM

$SNDX

0 · Reply

Jabed206 Oct. 25 at 2:45 AM

$SNDX

1 · Reply

DorisgtBoone Oct. 25 at 2:16 AM

#CVKD Exciting news: Cadrenal Therapeutics Company Webcast @ Lytham Partners Fall 2025 Investor Conference. Watch live here: https://youtu.be/NfPbBjgeIbg?si=2xPvJ2_YJQjHipGa $SNDX

0 · Reply

DLAT94 Oct. 25 at 1:59 AM

$SNDX Well, this didn’t go exactly according to plan. If there had been a run-up beforehand, I’d understand the sell-off after the PDUFA announcement, but without a run-up? Nevertheless, I remain extremely confident in this company and its two drugs for the foreseeable future (at least until the combo studies arrive). Since I missed the party after the trading halt yesterday, I’m hoping to be able to add significantly to my position at the current lower price. Goal: 16k shares, average $11. Expect this to get to at least 2b+ market cap. Glta.

2 · Reply

sfb_26 Oct. 25 at 1:57 AM

$SNDX The recent candle closed near the low of day momentum still to the downside. However, oversold RSI + volume climax suggests we’re near a potential short-term exhaustion point.

0 · Reply

LiquidThetaLEAPS Oct. 25 at 1:49 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SNDX Current Share Price: $14.92 Contracts: $SNDX January 15, 2027 $15 Calls Scale in: $4.45- $5.44 Scale out: $6.93-$8.91 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Habanacuba Oct. 25 at 1:31 AM

$SNDX If the drug were as bad as some shorts say, why did the FDA approve it?

0 · Reply

SnoopDawg Oct. 25 at 1:25 AM

$SNDX everyone posting why to hold ... why its so good... just sell. Sooner the mms get their stock the sooner the rest of us ride.

0 · Reply

dgbio Oct. 24 at 11:45 PM

$SNDX Kura has traded lower efficacy for better safety. Revu vs zifto: ORR, 47% vs 33%, median OS in responders, 23 month vs 18 month, transplants, 11% vs 2%. Revu's discontinuation rate is only about 5% and even these 5% are matched by the pediatric market (about 6% of NPM1) which only Syndax has. Kura is going to have an uphill battle to win an equal share in NPM1, while the KM2TAr market is for Syndax only.

1 · Reply

Brokester Oct. 24 at 11:20 PM

$SNDX

1 · Reply

cchronobreak Oct. 24 at 11:01 PM

$SNDX

0 · Reply

Ronasongs Oct. 24 at 10:37 PM

$SNDX Learning lesson to myself. When a stock is shorted nearly 30% by the MM's, they will get their money. Im holding, averaged down.

0 · Reply

Market Cap	1.26B
Revenue (ttm)	23.68M
Net Income (ttm)	-318.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,346.11%
Debt to Equity Ratio	2.18

Volume	14,941,400
Avg Vol	2,502,820
Day's Range	N/A - N/A
Shares Out	86.14M
Stochastic %K	17%
Beta	0.68
Analysts	Strong Sell
Price Target	$37.69